Cross-source evidence timeline
Cetrorelix research timeline
Follow 56 selected, directly cited source records from August 11, 2000 through November 9, 2026. This timeline joins source lanes for navigation; it does not infer that one record confirms another.
Source year
2026
Clinical trials
ClinicalTrials.gov record NCT05326087↗
PeptideScanner retained ClinicalTrials.gov record NCT05326087 at 2026-11-15T19:17:31.036Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
Comparison of Chitosan-Poloxamer Nanoparticles and Poloxamer-based In-Situ Forming Gel for Nose-to-Brain Delivery of Cetrorelix: In Vitro and Pharmacokinetic Studies in Rats.↗
PubMed lists PMID 42243608 in AAPS PharmSciTech as Journal Article, Comparative Study, with publication-date metadata of 2026-06-04 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 4, 2026 · day precisionAdded to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA218740↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 218740 with status AP dated 2026-04-29, and names cetrorelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT05951400↗
PeptideScanner retained ClinicalTrials.gov record NCT05951400 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-15, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT02892942↗
PeptideScanner retained ClinicalTrials.gov record NCT02892942 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-04-03, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT06378268↗
PeptideScanner retained ClinicalTrials.gov record NCT06378268 at 2026-11-15T22:02:39.332Z. Its registry update date was 2026-03-20, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
Extrahepatic in vitro metabolism of peptides; comparison of human kidney and intestinal S9 fraction, human plasma and proximal tubule cells, using cyclosporine A, leuprorelin, and cetrorelix as model…↗
PubMed lists PMID 36630767 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2022-12-31 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: December 31, 2022 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Synthesis of Diastereomerically Pure Cetrorelix Acetate by Using Fmoc Solid-Phase Peptide Synthesis (SPPS) Strategy: A Commercially Viable Approach.↗
PubMed lists PMID 40386934 in Journal of peptide science : an official publication of the European Peptide Society as Journal Article, with publication-date metadata of 2025-06 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 2025 · month precisionAdded to PeptideScanner November 15, 2026
Source year
2025
Regulatory
Drugs@FDA application ANDA218061↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 218061 with status AP dated 2025-06-03, and names cetrorelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT04414748↗
PeptideScanner retained ClinicalTrials.gov record NCT04414748 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-05-31, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT06608186↗
PeptideScanner retained ClinicalTrials.gov record NCT06608186 at 2026-11-15T22:02:39.332Z. Its registry update date was 2025-01-22, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026
Source year
2024
Clinical trials
ClinicalTrials.gov record NCT05767086↗
PeptideScanner retained ClinicalTrials.gov record NCT05767086 at 2026-11-15T22:02:39.332Z. Its registry update date was 2024-10-15, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
Cetrorelix in reproductive medicine.↗
PubMed lists PMID 37223762 in F&S reports as Journal Article, with publication-date metadata of 2022-11-21 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: November 21, 2022 · day precisionAdded to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA218150↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 218150 with status AP dated 2024-04-25, and names cetrorelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA214540↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 214540 with status AP dated 2024-04-24, and names cetrorelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026Regulatory
Drugs@FDA application ANDA217776↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 217776 with status AP dated 2024-04-16, and names cetrorelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026
Source year
2022
Regulatory
Drugs@FDA application ANDA215737↗
The official Drugs@FDA dataset lists original submission 1 for ANDA 215737 with status AP dated 2022-08-12, and names cetrorelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026
Source year
2021
Literature metadata
Use of cetrorelix in the investigation of testosterone excess in a postmenopausal woman.↗
PubMed lists PMID 22696667 in BMJ case reports as Case Reports, Journal Article, with publication-date metadata of 2011-04-26 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: April 26, 2011 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
In vivo biodistribution of an androgen receptor avid PET imaging agent 7-alpha-fluoro-17 alpha-methyl-5-alpha-dihydrotestosterone ([(18)F]FMDHT) in rats pretreated with cetrorelix, a GnRH antagonist.↗
PubMed lists PMID 17934727 in European journal of nuclear medicine and molecular imaging as Journal Article, Research Support, N.I.H., Extramural, with publication-date metadata of 2007-10-13 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 13, 2007 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Fluorescence spectroscopic determination of the critical aggregation concentration of the GnRH antagonists Cetrorelix, Teverelix and Ozarelix.↗
PubMed lists PMID 20514551 in Journal of fluorescence as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2010-06-01 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 1, 2010 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Hepatic in vitro metabolism of peptides; Comparison of human liver S9, hepatocytes and Upcyte hepatocytes with cyclosporine A, leuprorelin, desmopressin and cetrorelix as model compounds.↗
PubMed lists PMID 33548873 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2021-01-27 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: January 27, 2021 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Identification and structural elucidation of a new cetrorelix methylene dimer impurity in cetrorelix acetate by using LC-MS/MS.↗
PubMed lists PMID 33611089 in Journal of pharmaceutical and biomedical analysis as Journal Article, with publication-date metadata of 2021-02-03 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 3, 2021 · day precisionAdded to PeptideScanner November 15, 2026
Source year
2020
Clinical trials
ClinicalTrials.gov record NCT03291821↗
PeptideScanner retained ClinicalTrials.gov record NCT03291821 at 2026-11-15T22:02:39.332Z. Its registry update date was 2020-12-29, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT04418908↗
PeptideScanner retained ClinicalTrials.gov record NCT04418908 at 2026-11-15T22:02:39.332Z. Its registry update date was 2020-06-05, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026
Source year
2019
Literature metadata
Development and validation of a HPLC method for routine quantification of the decapeptide Cetrorelix in liposome dispersions.↗
PubMed lists PMID 15019030 in Journal of pharmaceutical and biomedical analysis as Journal Article, Validation Study, with publication-date metadata of 2004-03-10 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: March 10, 2004 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
Modification of the in vitro release profile of Cetrorelix by complexation with biophilic partners.↗
PubMed lists PMID 18855603 in Current drug delivery as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2008-10 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 2008 · month precisionAdded to PeptideScanner November 15, 2026Literature metadata
Adsorption of the decapeptide Cetrorelix depends both on the composition of dissolution medium and the type of solid surface.↗
PubMed lists PMID 14757490 in European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences as Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2004-02 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 2004 · month precisionAdded to PeptideScanner November 15, 2026Literature metadata
Cetrorelix in the treatment of female infertility and endometriosis.↗
PubMed lists PMID 17020439 in Expert opinion on pharmacotherapy as Journal Article, Review, with publication-date metadata of 2006-10 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 2006 · month precisionAdded to PeptideScanner November 15, 2026Literature metadata
Phase II study of cetrorelix, a luteinizing hormone-releasing hormone antagonist in patients with platinum-resistant ovarian cancer.↗
PubMed lists PMID 13678723 in Gynecologic oncology as Clinical Trial, Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't, and 1 more PubMed publication type, with publication-date metadata of 2003-09 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 2003 · month precisionAdded to PeptideScanner November 15, 2026Literature metadata
Luteinizing hormone-releasing hormone antagonist cetrorelix as primary single therapy in patients with advanced prostatic cancer and paraplegia due to metastatic invasion of spinal cord.↗
PubMed lists PMID 7531902 in Urology as Clinical Trial, Journal Article, with publication-date metadata of 1995-02 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: February 1995 · month precisionAdded to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT02042196↗
PeptideScanner retained ClinicalTrials.gov record NCT02042196 at 2026-11-15T22:02:39.332Z. Its registry update date was 2019-07-11, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT03759301↗
PeptideScanner retained ClinicalTrials.gov record NCT03759301 at 2026-11-15T22:02:39.332Z. Its registry update date was 2019-06-24, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Literature metadata
The LHRH antagonist cetrorelix: a review.↗
PubMed lists PMID 10972520 in Human reproduction update as Journal Article, Review, with publication-date metadata of 2000 Jul-Aug (source-text precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: 2000 Jul-Aug · source-text precisionAdded to PeptideScanner November 15, 2026Literature metadata
Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'?↗
PubMed lists PMID 12151431 in Human reproduction (Oxford, England) as Clinical Trial, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2002-08 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 2002 · month precisionAdded to PeptideScanner November 15, 2026Literature metadata
Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix.↗
PubMed lists PMID 9363724 in Human reproduction (Oxford, England) as Clinical Trial, Journal Article, with publication-date metadata of 1997-09 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 1997 · month precisionAdded to PeptideScanner November 15, 2026Literature metadata
Treatment of uterine fibroids with a slow-release formulation of the gonadotrophin releasing hormone antagonist Cetrorelix.↗
PubMed lists PMID 9688409 in Human reproduction (Oxford, England) as Clinical Trial, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1998-06 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: June 1998 · month precisionAdded to PeptideScanner November 15, 2026
Source year
2018
Clinical trials
ClinicalTrials.gov record NCT01112358↗
PeptideScanner retained ClinicalTrials.gov record NCT01112358 at 2026-11-15T22:02:39.332Z. Its registry update date was 2018-08-28, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026
Source year
2017
Clinical trials
ClinicalTrials.gov record NCT01402336↗
PeptideScanner retained ClinicalTrials.gov record NCT01402336 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-10-10, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01565265↗
PeptideScanner retained ClinicalTrials.gov record NCT01565265 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-05-01, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01457703↗
PeptideScanner retained ClinicalTrials.gov record NCT01457703 at 2026-11-15T22:02:39.332Z. Its registry update date was 2017-01-12, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026
Source year
2016
Clinical trials
ClinicalTrials.gov record NCT02784457↗
PeptideScanner retained ClinicalTrials.gov record NCT02784457 at 2026-11-15T22:02:39.332Z. Its registry update date was 2016-05-27, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT02333253↗
PeptideScanner retained ClinicalTrials.gov record NCT02333253 at 2026-11-15T22:02:39.332Z. Its registry update date was 2016-01-27, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026
Source year
2015
Clinical trials
ClinicalTrials.gov record NCT02640976↗
PeptideScanner retained ClinicalTrials.gov record NCT02640976 at 2026-11-15T22:02:39.332Z. Its registry update date was 2015-12-29, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026
Source year
2014
Clinical trials
ClinicalTrials.gov record NCT01109654↗
PeptideScanner retained ClinicalTrials.gov record NCT01109654 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-07-16, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01225835↗
PeptideScanner retained ClinicalTrials.gov record NCT01225835 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-03-14, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT01185704↗
PeptideScanner retained ClinicalTrials.gov record NCT01185704 at 2026-11-15T22:02:39.332Z. Its registry update date was 2014-02-13, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026
Source year
2013
Literature metadata
A pilot study to assess the use of the gonadotrophin antagonist cetrorelix in preserving ovarian function during chemotherapy.↗
PubMed lists PMID 21810087 in The Australian & New Zealand journal of obstetrics & gynaecology as Journal Article, with publication-date metadata of 2011-08-02 (day precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: August 2, 2011 · day precisionAdded to PeptideScanner November 15, 2026Literature metadata
[Medical treatment of uterine fibroids with the LHRH antagonist: Cetrorelix].↗
PubMed lists PMID 10605180 in Contraception, fertilite, sexualite (1992) as Clinical Trial, English Abstract, Journal Article, Randomized Controlled Trial, with publication-date metadata of 1999-10 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: October 1999 · month precisionAdded to PeptideScanner November 15, 2026Literature metadata
[Use of GnRH antagonists (cetrorelix) in assisted reproduction: first report in Mexican literature].↗
PubMed lists PMID 12448050 in Ginecologia y obstetricia de Mexico as Comparative Study, English Abstract, Journal Article, with publication-date metadata of 2002-09 (month precision). PeptideScanner associated the retained record with the identity slug cetrorelix. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.↗
Attributed publication date: September 2002 · month precisionAdded to PeptideScanner November 15, 2026
Source year
2012
Clinical trials
ClinicalTrials.gov record NCT00667758↗
PeptideScanner retained ClinicalTrials.gov record NCT00667758 at 2026-11-15T22:02:39.332Z. Its registry update date was 2012-08-06, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026
Source year
2010
Clinical trials
ClinicalTrials.gov record NCT00746031↗
PeptideScanner retained ClinicalTrials.gov record NCT00746031 at 2026-11-15T22:02:39.332Z. Its registry update date was 2010-10-25, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00439829↗
PeptideScanner retained ClinicalTrials.gov record NCT00439829 at 2026-11-15T22:02:39.332Z. Its registry update date was 2010-05-25, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026
Source year
2008
Clinical trials
ClinicalTrials.gov record NCT00244452↗
PeptideScanner retained ClinicalTrials.gov record NCT00244452 at 2026-11-15T22:02:39.332Z. Its registry update date was 2008-03-31, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026Clinical trials
ClinicalTrials.gov record NCT00628121↗
PeptideScanner retained ClinicalTrials.gov record NCT00628121 at 2026-11-15T22:02:39.332Z. Its registry update date was 2008-03-04, and PeptideScanner's reviewed identity mapping was cetrorelix.↗
Added to PeptideScanner November 15, 2026
Source year
2006
Regulatory
Federal Register notice E6-9031↗
The Federal Register published notice E6-9031, attributed to FDA and its parent HHS department, on 2006-06-09. Its official title is “Determination of Regulatory Review Period for Purposes of Patent Extension; CETROTIDE,” and PeptideScanner's exact reviewed identity mapping connects the document to Cetrorelix.↗
Added to PeptideScanner November 15, 2026
Source year
2000
Regulatory
Drugs@FDA application NDA021197↗
The official Drugs@FDA dataset lists original submission 1 for NDA 021197 with status AP dated 2000-08-11, and names cetrorelix acetate among the application record's active ingredients.↗
Added to PeptideScanner November 15, 2026